CDK4 and cancer: The Cancer Genome Atlas (TCGA) project has shown that CDKN2A/p16-CDK4/6-RB pathway is altered in nearly 80 % of primary GBMs with the most frequent genetic alterations being CDKN2A gene deletion or mutation, CDK4 amplification, and RB1 mutation or deletion [9, 10].